not losing weight on a glp 1 Why is my GLP-1 medication working? To GLP-1 or Not to

Ask your provider if they carry Akkermansia

New users are taking them primarily for weight loss, and most are women, particularly those without diabetes

doi: 10.2337/dc13-1066

Food and Drug Administration for the treatment of chronic weight management in those with obesity or overweight who have at least one weight-related condition

Musso G, Gambino R, Tabibian JH, Ekstedt M, Kechagias S, Hamaguchi M, Hultcrantz R, Hagstrm H, Yoon SK, Charatcharoenwitthaya P, George J, Barrera F, Hafliadttir S, Bjrnsson ES, Armstrong MJ, Hopkins LJ, Gao X, Francque S, Verrijken A, Yilmaz Y, Lindor KD, Charlton M, Haring R, Lerch MM, Rettig R, Vlzke H, Ryu S, Li G, Wong LL, Machado M, Cortez-Pinto H, Yasui K, Cassader M

Q2 2025 Snapshot Eli Lilly and Company dominates the US 57 % GLP-1 share, led by Mounjaro (tirzepatide) HCP & Zepbound (tirzepatide) HCP Novo Nordisk rules Europe 63 % value share, powered by Wegovy(semaglutide) injection 2.4 mg HCP & Ozempic APAC & Emerging Markets are the next frontier (+1113 % YoY) Together, they crossed $24 Billion in H1 2025 GLP-1 revenue proving the real blockbuster of this decade isnt oncology or immunology Its metabolic health